Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

Table 3 Scores of the clinimetric test for articular-gastrointestinal activity and patient reported outcomes of health-related quality of life

	Baseline	T6	T12
CDAI, n = 19	181.3 ± 93.2	112.3 ± 63.0b	82.7 ± 48.7b
pMAYO, n = 11	3.27 ± 1.79	1.81 ± 1.07a	1.63 ± 1.43a
IBDQ	145.3 ± 36.8	172.8 ± 36.7e	180.7 ± 33.0e
BASDAI	5.5 ± 1.7	3.2 ± 1.8e	3.3 ± 1.7e
BASFI	3.2 ± 2.4	1.8 ± 1.4e	2.0 ± 1.3a
ASDAS-CRP	3.2 ± 0.8	1.9 ± 0.6e	1.9 ± 0.6e
PtGA	61.1 ± 20.6	35.6 ± 19.1b	33.0 ± 19.1b
HAQ	4.7 ± 8.5	2.0 ± 4.2a	1.6 ± 3.5a
Sf-36/PCS	42.2 ± 9.7	48.4 ± 7.2e	48.5 ± 7.3b
Sf-36/MCS	35.4 ± 10.9	39.4 ± 8.8a	41.4 ± 9.7a
CRP in mg/dL	2.7 ± 3.7	0.8 ± 1.2a	0.5 ± 0.6a

^aP < 0.05,

^bP < 0.01,

^eP < 0.001. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CDAI: Crohn’s Disease Activity Index; CRP: C-Reactive Protein; pMAYO: partial Mayo score; HAQ: Health Assessment Questionnaire; IBDQ: Inflammatory Bowel Disease Questionnaire; PtGA: Patient Global Assessment; SF-36/MCS: Summary of “Mental Component Score” of the Short Form-36 health survey; SF-36/PCS: Summary of “Physical Component Score” of the Short Form-36 health survey; T6 and T12: Results of the evaluation after 6 mo and 12 mo of treatment with adalimumab respectively.